Kaisa
Huhtinen
Docent, Faculty of Medicine
Senior Research Fellow, Biotechnology
PhD, Adjunct Professor in Cancer Biology
Areas of expertise
Ovarian cancer
personalized medicine
early diagnostics
prediction
prognosis
biomarker
genomics
drug target
interdicipline research;
Publications
American Association for Cancer Research Special Conference on Advances in Ovarian Cancer Research Sep 13-16, 2019 Atlanta, GA, USA Abstracts (2020)
Clinical Cancer Research
(O2 Muu julkaisu )
Singling out tumor heterogeneity and chemoresistance in high-grade serous ovarian cancer (2020)
Clinical Cancer Research
(O2 Muu julkaisu )
A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer (2020)
Gynecologic Oncology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125 (2020)
Communications Biology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
CtDNA profiling to predict prognosis and optimize treatment in high-grade serous ovarian cancer (2019)
Clinical Cancer Research
(O2 Muu julkaisu )
Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources (2019)
The Journal of Applied Laboratory Medicine
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer (2019)
JCO Precision Oncology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer (2018)
Oncology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
A cancer-specific detection of serum CA125 improves differential diagnosis of epithelial ovarian cancer from benign conditions. (2018)
Clinical Cancer Research
(O2 Muu julkaisu )
High-throughput screening of new potential targets for high-grade serous ovarian cancer treatment (2018)
Clinical Cancer Research
(O2 Muu julkaisu )